A recent study indicates that over half of cancer patients in the Midlands who had their genomes sequenced through the 100,000 Genomes Project received clinical guidance.
Nearly 60% of those who participated in the 100,000 Genomes Project through the West Midlands Genomic Medicine Service Alliance had their genome sequencing results evaluated by a specialized genomic multidisciplinary team, leading to clinical recommendations.
Approximately 40.4% of participants received potential treatment options, including both licensed and unlicensed medications, as well as opportunities for clinical trials. However, only a few of these recommendations resulted in actual modifications to the patients’ cancer treatment plans.
A research paper published in The British Journal of Cancer, led by Professor Andrew Beggs and his research team at the University of Birmingham, in partnership with The West Midlands Regional Genomics Laboratory, the Central and South Genomic Medicine Service Alliance, and The Wessex NHS Genomics Medicine Centre, assessed how the 100,000 Genomes Project was deployed for cancer patients in the region.
Professor Beggs remarked:
“The findings from this study on comprehensive genome sequencing for cancer patients in our area are particularly notable due to the diverse nature of our local demographic, which includes various minority ethnic groups and a wide range of socioeconomic backgrounds.”
“We hope that whole genome sequencing may unlock treatment options for patients who currently have very few. Additionally, with extended follow-up, more participants could potentially access tailored medical options based on their genome sequencing results, especially during instances of disease recurrence.”
A Pioneering Project
The 100,000 Genomes Project stands as a pioneering initiative in the UK, assessing the viability and advantages of complete genome sequencing for cancers and rare diseases.
The research revealed that various cancer types displayed different rates of recommended treatments. For instance, 53.7% of participants with lung cancer received potential treatment or trial suggestions, compared to just 13.3% of those with blood cancer. Additionally, patients with breast and pediatric cancers were more frequently directed to clinical genetic services.
During the study, there was noticeable progress in patient recruitment, sample quality, and the speed of sequencing, which improved from 16 weeks to just 4 weeks by the study’s conclusion. This indicates that the project has effectively contributed to building the necessary infrastructure and expertise for the efficient delivery of whole genome sequencing.
Dr. Helen Robbins from the University of Birmingham, a co-author of the study, stated:
“This research assessed the clinical value of whole genome sequencing for cancer patients. The 100,000 Genomes Project took an inclusive approach to sequencing, not excluding patients based on stage, grade, or prognosis.
“While this method enhances our biological understanding of malignancies, it also means that a significant number of patients whose genomes were sequenced did not experience any changes in their cancer management.”
